Ibotenic Acid Mushroom Toxicity Clinical Presentation

  • Author: Peter A Chyka, PharmD, FAACT, DABAT; Chief Editor: Timothy E Corden, MD   more...
 
Updated: Jun 1, 2011
 

History

Ask the patient about how many mushrooms were consumed, how they were prepared, and when the mushrooms were eaten. The concentration of active substances is low in any one mushroom, but generally about 1 mushroom in young children and 3 or more in adolescents and adults produce toxic symptoms.[10] The effects of mushrooms vary greatly, and cooking may not alter toxicity. An amount as small as a mouthful can cause symptoms.[9]

Obtain a history of the exposure that includes the following:

  • Quantity of mushrooms ingested
  • Preparation of the mushroom (eg, raw, cooked)
  • Source of the mushroom (eg, outdoors, the Internet)
  • Time of the ingestion
  • Symptoms and time of onset after ingestion
  • Prehospital treatment including home remedies
  • Medications regularly taken and any coingestants

The timing of symptom onset is a crucial element of the history in differentiating life-threatening or severe mushroom poisonings from those that are less serious and typically have an onset of symptoms well within 5 hours of ingestion such as the mushrooms of the ibotenic acid group.[4, 5, 1, 2, 3]

Mushrooms from the cyclopeptide (Amanita phalloides) or orellanine (Cortinarius mushrooms) groups that can produce hepatic or renal failure, respectively, typically produce symptoms 6-24 h after ingestion.

Amanita smithiana (allenic norleucine group) found in the Northwestern states can also be nephrotoxic, but it has an onset of gastrointestinal distress within 1-12 hours.[15] These mushrooms are often confused with edible pine mushrooms.

For mushroom ingestions in the Pacific Northwest region of the United States, patients who have early-onset symptoms (< 3 h after ingestion) and remain symptomatic should be fully evaluated in a hospital until the mushroom identity is confirmed to be nontoxic or the patient’s condition improves.[3]

Identification of the actual mushroom consumed is important but is typically impossible because the mushroom in question has already been digested.

A muscaria has a scarlet cap, is 5-30 cm in diameter and contains white warts. The stalk is white, is frequently hollow, and is often as long as 15-20 cm. A prominent cup (volva) is found at the bottom of the stalk, with numerous rings superiorly. The gills of A muscaria are free and white. The spores are also white. Its appearance can vary depending on the geographic location. The scarlet cap is predominantly found in western North America. Caps that are orange to yellow-orange caps are most frequent in eastern North America.

A muscaria can occur alone or in groups on the ground of forests, in grassy areas and lawns, and especially under trees.

Different types of mushrooms can be found in the same location, and a single sample can lead to false identification of the mushroom that was ingested. Consider all possible mushrooms in the immediate vicinity of where the ingestion occurred.

When no specimen is brought in by a patient with a suspected mushroom ingestion, sending an experienced forager to the site to collect any mushrooms growing in the area might be helpful.

When mushrooms are obtained for identification, the entire mushroom should be dug up to preserve the architecture of the bulb, stem, and cap. Place individual mushrooms in a dry paper bag, not a plastic or cloth bag. Transporting the mushrooms in a careful, dry manner minimizes destruction of the natural architecture of the mushrooms, discoloration of the cap or gills, and premature release of the spores. Do not refrigerate or crush the mushrooms.

Collecting the patient's gastric contents by means of gastric lavage or after emesis might yield identifiable spores.

Remote viewing of the mushroom by digital photography and Internet transmission may aid the identification of unknown mushrooms by mycologists.[16]

Next

Physical

Once ingested, A muscaria produces symptoms within 30-90 minutes. Peak effects occur at 2-3 hours. The initial symptom is drowsiness, followed by confusion, ataxia, dizziness, euphoria, and intoxication. These symptoms can proceed to hyperkinesis, muscle jerks, spasms, and delirium. Deep sleep or coma can occur and generally lasts 4-8 hours.

  • If symptoms such as vomiting, diarrhea, and abdominal pain begin 5 hours or more after ingestion, poisoning with the potentially life-threatening or severe mushrooms such as the cyclopeptide (Amanita phalloides) or orellanine (Cortinarius mushrooms) groups, which can produce hepatic or renal failure, respectively, should be considered.[4, 5, 1, 2, 3]Amanita smithiana (allenic norleucine group) found in the Northwestern United States can also be nephrotoxic, but it has an onset of gastrointestinal distress within 1-12 hours after ingestion.[15] For mushroom ingestions in the Pacific Northwest region of the United States, patients who have early-onset symptoms (< 3 h after ingestion) and remain symptomatic should be fully evaluated in a hospital until the mushroom identity is confirmed or the patient's condition improves.[3]
  • Vital signs: Pulse and blood pressure are usually unchanged.
  • Respiration: Breathing is slow and regular, similar to that in deep sleep.
  • GI: GI upset and vomiting occur but are not common. When vomiting or diarrhea does occur, fluid and electrolyte changes are uncommon.
  • Integumentary: Skin may be reddened and warm to the touch.
  • Musculoskeletal: Muscle spasms may occur.
  • Neurologic: Agitation and CNS depression may occur. Especially in children, tonic-clonic seizures, fasciculations, and myoclonic jerking lasting 6-9 hours have been reported.[9] Seizures in adults are uncommon. Initial excitation leads to stupor, then coma; severe lethargy alternating with agitation is common, and a deep sleep may occur. Agitation, babbling, confusion, screaming, irritability, hallucinations, dizziness, ataxia, euphoria progressing to muscle jerks, spasms, delirium, racing thoughts, and giddiness may be seen. Headache may last several days. Illusions of sight and sound are produced by misinterpretation of sensory input.
Previous
Next

Causes

  • Incorrect mushroom identification by a naive forager such as an immigrant who mistakes one of the local poisonous varieties for an edible mushroom native to his or her homeland or a novice mushroom harvester
  • Intentional ingestion by a suicidal person
  • Unintentional ingestion by a child who found mushrooms growing in yards or outdoor play areas
  • Foul play in which an individual is poisoned by someone else
  • Inadvertent poisoning from dried mushrooms purchased on the Internet or from other sources where the composition of the mushroom is unreliable or where the mushroom might contaminated with unknown toxic compounds
Previous
 
 
Contributor Information and Disclosures
Author

Peter A Chyka, PharmD, FAACT, DABAT  Professor and Executive Associate Dean, College of Pharmacy, University of Tennessee Health Science Center

Peter A Chyka, PharmD, FAACT, DABAT is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Clinical Pharmacy, and American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

Coauthor(s)

William Banner Jr, MD, PhD  Medical Director, Oklahoma Poison Control Center; Clinical Professor of Pharmacy, Oklahoma University College of Pharmacy-Tulsa; Adjunct Clinical Professor of Pediatrics, Oklahoma State University College of Osteopathic Medicine

William Banner Jr, MD, PhD, is a member of the following medical societies: American College of Medical Toxicology

Disclosure: Nothing to disclose.

Specialty Editor Board

Michael E Mullins, MD  Assistant Professor, Department of Emergency Medicine, Washington University School of Medicine

Michael E Mullins, MD is a member of the following medical societies: American Academy of Clinical Toxicology and American College of Emergency Physicians

Disclosure: Johnson & Johnson stock ownership None; Savient Pharmaceuticals stock ownership None

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Jeffrey R Tucker, MD  Assistant Professor, Department of Pediatrics, Division of Emergency Medicine, University of Connecticut and Connecticut Children's Medical Center

Disclosure: Merck Salary Employment

Daniel Rauch, MD, FAAP  Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine

Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine

Disclosure: Baxter Honoraria Consulting

Chief Editor

Timothy E Corden, MD  Associate Professor of Pediatrics, Co-Director, Policy Core, Injury Research Center, Medical College of Wisconsin; Associate Director, PICU, Children's Hospital of Wisconsin

Timothy E Corden, MD is a member of the following medical societies: American Academy of Pediatrics, Phi Beta Kappa, Society of Critical Care Medicine, and Wisconsin Medical Society

Disclosure: Nothing to disclose.

References
  1. Berger KJ, Guss DA. Mycotoxins revisited: Part I. J Emerg Med. Jan 2005;28(1):53-62. [Medline].

  2. Berger KJ, Guss DA. Mycotoxins revisited: Part II. J Emerg Med. 2005b Feb;28(2):175-83. [Medline].

  3. Goldfrank LR. Mushrooms. In: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE. Goldfrank's Toxicologic Emergencies. 9th ed. New York: McGraw-Hill; 2011:1522-36.

  4. Diaz JH. Evolving global epidemiology, syndromic classification, general management, and prevention of unknown mushroom poisonings. Crit Care Med. Feb 2005;33(2):419-26. [Medline].

  5. Diaz JH. Syndromic diagnosis and management of confirmed mushroom poisonings. Crit Care Med. Feb 2005;33(2):427-36. [Medline].

  6. Watson WA, Litovitz TL, Rodgers GC Jr, Klein-Schwartz W, Reid N, Youniss J, et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. Sep 2005;23(5):589-666. [Medline]. [Full Text].

  7. Michelot D, Melendez-Howell LM. Amanita muscaria: chemistry, biology, toxicology, and ethnomycology. Mycol Res. Feb 2003;107(Pt 2):131-46. [Medline].

  8. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Griffin SL. 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clin Toxicol (Phila). 2010;48:979-1178. [Full Text].

  9. Benjamin DR. Mushroom poisoning in infants and children: the Amanita pantherina/muscaria group. J Toxicol Clin Toxicol. 1992;30(1):13-22. [Medline].

  10. Poisindex managements, mushrooms - muscimol / ibotenic acid. In: Poisindex System [Internet database online] [database online]. Greenwood Village (CO): Thomson Reuters (Healthcare); May 17, 2011.

  11. Brvar M, Mozina M, Bunc M. Prolonged psychosis after Amanita muscaria ingestion. Wien Klin Wochenschr. May 2006;118(9-10):294-7. [Medline].

  12. Satora L, Pach D, Butryn B, Hydzik P, Balicka-Slusarczyk B. Fly agaric (Amanita muscaria) poisoning, case report and review. Toxicon. Jun 1 2005;45(7):941-3. [Medline].

  13. Satora L, Pach D, Ciszowski K, Winnik L. Panther cap Amanita pantherina poisoning case report and review. Toxicon. Apr 2006;47(5):605-7. [Medline].

  14. NAMA (North American Mycological Association). Annual reports. North American Mycological Association, Toxicology Section. Available at http://www.namyco.org/toxicology. Accessed May 17, 2011.

  15. West PL, Lindgren J, Horowitz BZ. Amanita smithiana mushroom ingestion: a case of delayed renal failure and literature review. J Med Toxicol. Mar 2009;5(1):32-8. [Medline].

  16. Fischbein CB, Mueller GM, Leacock PR, Wahl MS, Aks SE. Digital imaging: a promising tool for mushroom identification. Acad Emerg Med. Jul 2003;10(7):808-11. [Medline].

  17. Beuhler MC, Sasser HC, Watson WA. The outcome of North American pediatric unintentional mushroom ingestions with various decontamination treatments: an analysis of 14 years of TESS data. Toxicon. Mar 15 2009;53(4):437-43. [Medline].

  18. [Best Evidence] [Guideline] Chyka PA, Seger D, Krenzelok EP, Vale JA. Position paper: Single-dose activated charcoal. Clin Toxicol (Phila). 2005;43(2):61-87. [Medline]. [Full Text].

Previous
Next
 
Fly agaric (Amanita muscaria).
Amanita pantherina.
Amanita muscaria.
Amanita muscaria var. guessowii with a yellow cap surface, Massachusetts.
Amanita muscaria var. formosa sensu, Thiers, Oregon.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.